Access Pharmaceuticals Updates MuGard Website with New Video Featuring Clinical Feedback and Manufacturing Footage
DALLAS and NEW YORK, Oct. 14, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, has updated its MuGard website to include a clinical feedback video. The video features a late-stage colorectal patient and seasoned oncology nurse practitioner's experience with oral mucositis and MuGard. The video also features clips from Access' recent manufacturing run for MuGard. The clinical experience video will be utilized in Access' public relations marketing efforts for MuGard.
About MuGard:MuGard is a novel; ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments characterized by inflammation and ulceration of the mouth, tongue and throat. Up to 40% of all patients receiving chemotherapy and radiotherapy develop moderate to severe mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop mucositis. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatme